Bendamustine Synthesis Using Pre-built Bis-hydroxyethyl Starting Material
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current processes for producing bendamustine are inefficient due to the formation of impurities during hydroxyethylation, leading to reduced yields and increased costs, necessitating the development of a more cost-effective and safer industrial-scale synthesis method.
Innovation Solution
A novel synthetic route utilizing a compound with a pre-built bis-2-hydroxyethylamino moiety as the starting material, avoiding the need for toxic oxirane and reducing impurity formation, which allows for a higher yield and simplifies the synthesis by eliminating intermediate isolation and purification steps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the compound of formula (10) reacts with ethylene oxide to give compound (11), then the hydroxyethylation reaction occurs, but impurities are formed and yield is reduced
Solution Approach 1:
The patent applies preliminary action by using a starting material (compound of formula (13)) that already contains the pre-built bis-2-hydroxyethylamino moiety. This eliminates the need for the hydroxyethylation reaction step that generates impurities, as the hydroxyethyl groups are already present in the starting material before the synthetic sequence begins.
Solution Approach 2:
The patent extracts or removes the problematic hydroxyethylation reaction step from the synthesis pathway. By selecting a starting material that already contains the desired hydroxyethyl groups, the harmful reaction step that generates mono-hydroxyethyl impurities and reduces yield is completely eliminated from the process.
2Manufacturing precision
If elaborate purification procedures are used to remove impurities, then product purity is improved, but process cost increases
Solution Approach 1:
The patent converts the potential harm of impurity formation into a benefit by selecting a starting material that prevents impurity formation in the first place. The pre-built bis-2-hydroxyethylamino moiety in compound (13) ensures that no mono-hydroxyethyl impurities are generated, eliminating the need for elaborate purification procedures and reducing process costs.
Solution Approach 2:
By incorporating the hydroxyethyl groups into the starting material structure before synthesis begins, the patent preliminarily prevents the formation of impurities that would otherwise require costly purification steps to remove, thereby achieving both high purity and cost-effectiveness.
3Productivity
If toxic oxirane is used in the synthesis, then the hydroxyethylation reaction can proceed, but safety hazards increase
Solution Approach 1:
The patent extracts or removes the toxic oxirane (ethylene oxide) reagent from the synthesis pathway by using a starting material that already contains the hydroxyethyl groups. This eliminates the safety hazards associated with handling and using toxic oxirane while maintaining the desired reaction efficiency.
Solution Approach 2:
The patent replaces the toxic, hazardous oxirane reagent with a safer starting material (compound of formula (13)) that contains the pre-formed hydroxyethyl groups. This substitution eliminates safety hazards while maintaining or improving overall process efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves an overall isolated yield of more than 85%, significantly reducing resource burden and eliminating impurities, thus providing a more efficient and cost-effective method for producing bendamustine.
Implementation Method 1
reduction of the compound of formula (13), preferably by hydrogen under catalysis by a transition metal, to an amino compound of formula (14)
Data Source
AI summary
The invention deals with a novel process, and intermediates for making the pharmaceutically useful product bendamustine of formula (1), or a pharmaceutically acceptable salt thereof, said process inter alia being based on using the compound of formula (13) as the starting material.